Long-Acting HIV Therapy for Injection Drug Users
针对注射吸毒者的长效艾滋病毒治疗
基本信息
- 批准号:8054808
- 负责人:
- 金额:$ 71.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-01 至 2015-02-28
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAdherenceAlcoholsAnti-Retroviral AgentsAntibodiesCCR5 geneCaringChronic DiseaseCommunitiesControlled Clinical TrialsCounselingDevelopmentDirectly Observed TherapyDiseaseDoctor of MedicineDoseDouble-Blind MethodDropsDrug Delivery SystemsDrug abuseDrug resistanceDrug usageDrug userEnsureEpidemicFaceFailureGenerationsHIVHIV InfectionsHIV therapyHealth Services AccessibilityHighly Active Antiretroviral TherapyIllicit DrugsIndividualInfectionInjecting drug userInterventionIntravenousIntravenous infusion proceduresLifeLife ExpectancyMedicineMental DepressionMonitorMonoclonal AntibodiesMorbidity - disease rateNIH Program AnnouncementsNational Institute of Drug AbuseOralOral MedicinePRO 140PatientsPerceptionPharmaceutical PreparationsPilot ProjectsPlacebo ControlPopulationPrincipal InvestigatorPublic HealthRaceRandomizedRegimenResearchResearch PersonnelRiskSelf EfficacySocioeconomic StatusSubgroupTestingTreatment ProtocolsUnited StatesVertical Disease TransmissionViralViral Load resultViremiaVirusVulnerable Populationsantiretroviral therapybasecompliance behaviorimmune functionimprovedinnovationmortalitynovelopen labeloral careplacebo controlled studyprogramspublic health relevanceresponsesubcutaneoussuccesstransmission processtreatment durationtreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Combination antiretroviral therapy has provided many HIV-infected individuals with a near-normal life expectancy, provided they have access to care and can maintain strict lifetime adherence to the daily or more frequent treatment regimens. The most important factor in the virologic failure of an antiretroviral regimen is poor adherence of the patient to complete and proper dosing. HIV-infected IDUs face well-documented challenges to maintaining optimal adherence. Accordingly, this group, which represents approximately one- quarter of the U.S. HIV epidemic, has yet to derive the full benefits of the available antiretroviral therapies. Various interventions to improve antiretroviral drug adherence, ranging from counseling to directly-observed therapy and other structural interventions, have had only modest success. We propose a novel treatment strategy involving systemic administration of long-acting antiretroviral therapy as a means to ensure effective drug delivery and viral suppression in HIV-infected populations prone to poor drug-adherence. We propose a randomized, double-blind, placebo-controlled study of weekly subcutaneous treatment with the CCR5 monoclonal antibody PRO 140 in combination with a standard-of-care oral antiretroviral regimen. PRO 140 is uniquely suited for this use as it is the only HIV drug to demonstrate long-acting viral suppression without the need for slow IV infusion. Success in this pilot study would identify a new strategy for improving the care of HIV-infected IDUs and other vulnerable populations that are underserved by the current generation of antiretroviral medications. Positive results could catalyze this field and spur development and testing of other long-acting HIV drugs in this population.
PUBLIC HEALTH RELEVANCE: Combination antiretroviral therapy has provided many HIV-infected individuals with a near- normal life expectancy, provided they have access to care and can maintain strict lifetime adherence to the daily or more frequent treatment regimens. HIV-infected injection drug users (IDUs) face well-documented challenges to maintaining optimal adherence. Accordingly, this group, which represents approximately one-quarter of the HIV epidemic in the United States, has yet to derive the full benefits of the available antiretroviral therapies. We propose a novel treatment strategy involving systemic administration of long-acting antiretroviral therapy as a means to ensure effective drug delivery and viral suppression in HIV-infected populations prone to poor drug-adherence.
描述(由申请人提供):联合抗逆转录病毒治疗为许多艾滋病毒感染者提供了接近正常的预期寿命,前提是他们能够获得护理,并能够终身严格遵守每日或更频繁的治疗方案。抗逆转录病毒治疗方案病毒学失败的最重要因素是患者对完整和适当剂量的依从性差。感染艾滋病毒的注射吸毒者在保持最佳依从性方面面临有据可查的挑战。因此,这一群体占美国艾滋病毒流行病的大约四分之一,尚未获得可用抗逆转录病毒疗法的全部益处。从咨询到直接观察治疗和其他结构性干预措施,提高抗逆转录病毒药物依从性的各种干预措施只取得了一定的成功。我们提出了一种新的治疗策略,涉及系统管理的长效抗逆转录病毒治疗的手段,以确保有效的药物输送和病毒抑制艾滋病毒感染人群中容易出现药物依从性差。我们提出了一项随机、双盲、安慰剂对照的研究,每周皮下注射CCR5单克隆抗体PRO 140联合标准的口服抗逆转录病毒治疗方案。PRO 140非常适合这种用途,因为它是唯一一种证明长效病毒抑制而无需缓慢静脉输注的HIV药物。这一试点研究的成功将确定一项新的战略,以改善对感染艾滋病毒的注射吸毒者和其他弱势群体的护理,这些人得不到当前一代抗逆转录病毒药物的充分服务。积极的结果可能会促进这一领域的发展,并刺激其他长效艾滋病毒药物在这一人群中的开发和测试。
公共卫生相关性:联合抗逆转录病毒疗法使许多艾滋病毒感染者的预期寿命接近正常,条件是他们能够获得护理,并能够终生严格遵守每日或更频繁的治疗方案。感染艾滋病毒的注射吸毒者在保持最佳依从性方面面临有据可查的挑战。因此,这一群体约占美国艾滋病毒流行病的四分之一,尚未从现有的抗逆转录病毒疗法中充分获益。我们提出了一种新的治疗策略,涉及系统管理的长效抗逆转录病毒治疗的手段,以确保有效的药物输送和病毒抑制艾滋病毒感染人群中容易出现药物依从性差。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY M. JACOBSON其他文献
JEFFREY M. JACOBSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY M. JACOBSON', 18)}}的其他基金
Innate and adaptive defenses against SARS-COV-2 in the oral cavity during acute unvaccinated and breakthrough infections
急性未接种疫苗和突破性感染期间口腔针对 SARS-COV-2 的先天和适应性防御
- 批准号:
10667248 - 财政年份:2022
- 资助金额:
$ 71.58万 - 项目类别:
Long-acting, self-administered HIV therapy with th CCR5 antibody PRO 140
使用 CCR5 抗体 PRO 140 进行长效、自我管理的 HIV 治疗
- 批准号:
8541374 - 财政年份:2011
- 资助金额:
$ 71.58万 - 项目类别:
Long-acting, self-administered HIV therapy with th CCR5 antibody PRO 140
使用 CCR5 抗体 PRO 140 进行长效、自我管理的 HIV 治疗
- 批准号:
8546145 - 财政年份:2011
- 资助金额:
$ 71.58万 - 项目类别:
Long-Acting HIV Therapy for Injection Drug Users
针对注射吸毒者的长效艾滋病毒治疗
- 批准号:
8215745 - 财政年份:2010
- 资助金额:
$ 71.58万 - 项目类别:
Long-Acting HIV Therapy for Injection Drug Users
针对注射吸毒者的长效艾滋病毒治疗
- 批准号:
9178399 - 财政年份:2010
- 资助金额:
$ 71.58万 - 项目类别:
Long-Acting HIV Therapy for Injection Drug Users
针对注射吸毒者的长效艾滋病毒治疗
- 批准号:
8425102 - 财政年份:2010
- 资助金额:
$ 71.58万 - 项目类别:
Long-Acting HIV Therapy for Injection Drug Users
针对注射吸毒者的长效艾滋病毒治疗
- 批准号:
8603231 - 财政年份:2010
- 资助金额:
$ 71.58万 - 项目类别:
HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140
使用 CCR5 mAb PRO 140 进行 HIV 进入抑制剂治疗
- 批准号:
7575211 - 财政年份:2008
- 资助金额:
$ 71.58万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 71.58万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 71.58万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 71.58万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 71.58万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 71.58万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 71.58万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 71.58万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 71.58万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 71.58万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 71.58万 - 项目类别:
Fellowship Programs